ProCE Banner Activity

ANRS 12300 Reflate TB2: RAL + 3TC/TDF Does Not Achieve Noninferior Efficacy vs EFV + 3TC/TDF at Wk 48 in ART-Naive Adults With HIV and TB

Slideset Download
Conference Coverage
First-line raltegravir 400 mg BID achieved HIV-1 RNA < 50 copies/mL in 61% of patients vs 66% with efavirenz 600 mg QD, each combined with 3TC/TDF in HIV/TB-coinfected patients receiving rifampin.

Released: July 23, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner